AURINIA PHARMACEUTICALS INC (AUPH)

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals Becomes Oversold (AUPH)

Commit To Buy Aurinia Pharmaceuticals At $3, Earn 13.3% Using Options

Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Noteworthy Thursday Option Activity: SOUN, AUPH, APP

Aurinia Pharmaceuticals is Now Oversold (AUPH)

Aurinia stock drops after Q4 miss, failed strategic review

Aurinia Pharmaceuticals (AUPH) stock dropped 25% after disappointing with its Q4 results and failing in its strategic review. Read more here.

Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value

(NASDAQ:AUPH)

Aurinia Pharma is set to announce Q4 earnings results.

Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024

Noteworthy Monday Option Activity: SG, AUPH, EXEL

Noteworthy Thursday Option Activity: CROX, AUPH, PLOW

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 18.6% Using Options

Noteworthy Friday Option Activity: AUPH, DKNG, UVE

Notable Wednesday Option Activity: AUPH, MS, ALGM

Aurinia Pharma jumps amid takeover speculation

Aurinia Pharmaceuticals (AUPH) experiences a 7.3% surge amidst takeover rumors, fueled by a reported visit from Gilead Sciences (GILD) corporate jet.

Notable Wednesday Option Activity: AUPH, PSX, UTI

Aurinia partner files for Japan approval of lupus nephritis drug (NASDAQ:AUPH)

Aurinia Pharmaceuticals' collaboration partner, Otsuka Pharmaceutical, has filed a new drug application for voclosporin in Japan, aimed at treating lupus...

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

Aurinia Pharma stock spikes after Q3 beat (NASDAQ:AUPH)

Aurinia Pharmaceuticals (AUPH) reported better-than-expected Q3 2023 financials on Thursday driven by its lupus nephritis therapy Lupkynis. Read more here.

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023